Financial pioneering: The Genentech acquisition by Roche

The case describes the financing of the Genentech acquisition by Roche. The case explores the innovative way of financing by Roche at the beginning of 2009, just months after the Lehman Brothers bankruptcy. With equity markets in free fall, and with debt markets “shut off”, the CFO of Roche manages to finance an acquisition costing more than USD 40 billion, and scores three hits in a matter of weeks: a) the largest private issue of bonds in the US (USD 16.6 billion); b) the largest private issue of bonds in Continental Europe (Euro 11.25 billion); c) the largest private issue of bonds in UK (Sterling1.25 billion). The case presents the facts, the issues at stake, and the incredibly bold and innovative financiang route chosen by the Roche CFO.